Ads
related to: cure for glaucoma soon says new research process due to diabetes
Search results
Results from the WOW.Com Content Network
Diabetic retinopathy (also known as diabetic eye disease) is a medical condition in which damage occurs to the retina due to diabetes.It is a leading cause of blindness in developed countries and one of the lead causes of sight loss in the world, even though there are many new therapies and improved treatments for helping people live with diabetes.
BrightFocus Foundation is a nonprofit organization based in Clarksburg, Maryland.BrightFocus funds research in an effort to discover cures for Alzheimer's disease, macular degeneration and glaucoma, and provides information and free English and Spanish resources to increase awareness about these diseases.
Acetazolamide is an inhibitor of carbonic anhydrase.It is used for glaucoma, epilepsy (rarely), idiopathic intracranial hypertension, and altitude sickness. For the reduction of intraocular pressure (IOP), acetazolamide inactivates carbonic anhydrase and interferes with the sodium pump, which decreases aqueous humor formation and thus lowers IOP.
Novartis' eye care unit Alcon is withdrawing a surgical stent for glaucoma patients after clinical data showed it may damage the eye, but the Swiss drugmaker said the move would not affect plans ...
Glaucoma is a group of diseases affecting the optic nerve that results in vision loss and is frequently characterized by raised intraocular pressure (IOP). There are many glaucoma surgeries, and variations or combinations of those surgeries, that facilitate the escape of excess aqueous humor from the eye to lower intraocular pressure, and a few ...
Glaucoma medication is divided into groups based on chemical structure and pharmacologic action. The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure (IOP) in patients that have an increased intraocular pressure.
Studies with monkeys show that injecting high-insulin-producing forms of these cells into the animals can “cure” type-1 diabetes for about six months. Human trials are underway.
SGLT-2 inhibitors are relatively new drugs that treat type 2 diabetes. The first SGLT-2 inhibitor approved for use in the United States was dapagliflozin (Farxiga) , in 2014.
Ads
related to: cure for glaucoma soon says new research process due to diabetes